EL7.AI
StocksMediumUpdated×2•Originally published 6 May 2026•Updated 8 May 2026•
1 min read

Class Action Lawsuits Filed Against Gemini Space Station and ImmunityBio Over Misleading Claims

Key Facts

1Gemini Space Station (GEMI) faces a lawsuit alleging the concealment of a corporate pivot and executive turmoil in its IPO documents.
2GEMI stock has traded more than 75% below its IPO price following a series of negative disclosures.
3ImmunityBio (IBRX) is facing litigation following an FDA warning letter regarding misleading efficacy claims for its product Anktiva.

Gemini Space Station and ImmunityBio are facing securities class action lawsuits alleging violations of federal securities laws on the NASDAQ exchange. The litigation against Gemini Space Station (GEMI) cites concealed corporate pivots that led to a 75% drop in stock value from its IPO price. In a recent update, the law firm Bragar Eagel & Squire has joined the legal efforts against Gemini, with attorney Brandon Walker identified as the primary contact for affected investors. Simultaneously, ImmunityBio (IBRX) remains under scrutiny following an FDA warning regarding its drug, Anktiva. A critical 10-day deadline remains in place for impacted investors to join the legal action and seek recovery for their losses. These developments underscore the intensifying regulatory and legal risks facing both entities.